Literature DB >> 31880325

The creatine kinase conundrum: a reappraisal of the association of isotretinoin, creatine kinase, and rhabdomyolysis.

Justin W Marson1, Hilary E Baldwin2.   

Abstract

BACKGROUND: Isotretinoin has been reported to elevate creatine kinase, which may lead to fatal rhabdomyolysis.
OBJECTIVE: To review the literature and propose practice guidelines for management of elevated creatine kinase during isotretinoin therapy.
FINDINGS: Patients have intrinsic and extrinsic qualities that may synergistically work with isotretinoin to elevate serum creatine kinase. Darker skin types and males on isotretinoin are more likely to have elevated creatine kinase. Isotretinoin may induce oxidative stress within muscle tissue, thereby leading to elevations in serum creatine kinase.
CONCLUSION: Evidence supports a tenuous correlation between isotretinoin, elevated creatine kinase, and exercise. Physicians should consider obtaining baseline creatine kinase on elite athletes and counseling patients on risk factors that may elevate creatine kinase. However, the potential for elevated CK is not a contraindication for isotretinoin therapy.
© 2019 The International Society of Dermatology.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31880325     DOI: 10.1111/ijd.14758

Source DB:  PubMed          Journal:  Int J Dermatol        ISSN: 0011-9059            Impact factor:   2.736


  3 in total

1.  Isotretinoin Associated Rhabdomyolysis: Monitoring Creatine Kinase and Educating Patients.

Authors:  Folasade F Fayiga; Sophia C Reyes-Hadsall; Ludonir C Sebastiany; Sergey Arutyunyan; Alan Wong; Ana M Duarte
Journal:  Skin Appendage Disord       Date:  2021-07-28

2.  Rhabdomyolysis Caused by Isotretinoin and Exercise in an Otherwise Healthy Female Patient.

Authors:  Eli Raneses; Eric C Schmidgal
Journal:  Cureus       Date:  2022-06-15

3.  Evaluation of musculoskeletal adverse effects in patients on systemic isotretinoin treatment: A cross-sectional study.

Authors:  Emine Müge Acar; Senem Şaş; Fatmanur Aybala Koçak
Journal:  Arch Rheumatol       Date:  2021-12-24       Impact factor: 1.007

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.